Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

BACKGROUND: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. METHODS: We administered lambrolizuma...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D., Hersey, Peter, Joseph, Richard W., Weber, Jeffrey S., Dronca, Roxana, Gangadhar, Tara C., Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M., Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C., Chmielowski, Bartosz, Ebbinghaus, Scot W., Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni
格式: Artigo
語言:Inglês
出版: 2013
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126516/
https://ncbi.nlm.nih.gov/pubmed/23724846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1305133
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍